- Home
- DERM vs INBX Comparison
DERM vs INBX Comparison
Compare DERM & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DERM
- INBX
- Stock Information
- Founded
- DERM 2014
- INBX 2010
- Country
- DERM United States
- INBX United States
- Employees
- DERM N/A
- INBX N/A
- Industry
- DERM Biotechnology: Pharmaceutical Preparations
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- DERM Health Care
- INBX Health Care
- Exchange
- DERM Nasdaq
- INBX Nasdaq
- Market Cap
- DERM 181.0M
- INBX 178.5M
- IPO Year
- DERM 2021
- INBX 2020
- Fundamental
- Price
- DERM $7.15
- INBX $21.73
- Analyst Decision
- DERM Strong Buy
- INBX Hold
- Analyst Count
- DERM 1
- INBX 1
- Target Price
- DERM $9.00
- INBX N/A
- AVG Volume (30 Days)
- DERM 179.1K
- INBX 120.3K
- Earning Date
- DERM 08-11-2025
- INBX 08-12-2025
- Dividend Yield
- DERM N/A
- INBX N/A
- EPS Growth
- DERM N/A
- INBX N/A
- EPS
- DERM N/A
- INBX 111.58
- Revenue
- DERM $56,243,000.00
- INBX $200,000.00
- Revenue This Year
- DERM $28.99
- INBX N/A
- Revenue Next Year
- DERM $52.61
- INBX N/A
- P/E Ratio
- DERM N/A
- INBX $0.20
- Revenue Growth
- DERM N/A
- INBX N/A
- 52 Week Low
- DERM $3.54
- INBX $10.80
- 52 Week High
- DERM $8.25
- INBX $22.28
- Technical
- Relative Strength Index (RSI)
- DERM 53.22
- INBX 84.22
- Support Level
- DERM $6.78
- INBX $13.97
- Resistance Level
- DERM $7.34
- INBX $15.25
- Average True Range (ATR)
- DERM 0.35
- INBX 1.10
- MACD
- DERM 0.03
- INBX 0.66
- Stochastic Oscillator
- DERM 78.81
- INBX 95.32
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.